Stroke:非创伤性硬膜下出血和动脉缺血性事件的风险

2020-03-17 MedSci原创 MedSci原创

由此可见,在医疗保险受益人中,研究人员发现在非创伤性SDH后的4周内,由于缺血性卒中风险的增加,动脉缺血性事件的风险增加。这种风险的增加可能是由于SDH诊断后抗血栓治疗的中断所致。

硬膜下出血(SDH)后动脉缺血性事件的风险尚不清楚。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,该研究旨在评估创伤性SDH与非创伤性SDH患者急性缺血性卒中和心肌梗死的风险。

研究人员使用了2008年到2014年期间全国代表性医疗保险受益人索赔数据进行了一项回顾性队列研究。暴露因素为非创伤性SDH。该研究的主要结局是动脉缺血性事件,急性缺血性卒中和急性心肌梗死的复合事件。次要结局为单纯性缺血性卒中和单纯性心肌梗死。研究人员使用经验证的国际疾病分类临床修改诊断代码(第九次修订)来识别预测因素和结局。研究人员使用Cox回归和相应的生存概率,调整了人口统计学和血管并发症,计算了SDH出院后4周内的风险比。研究人员根据抗血栓治疗的较强适应证(房颤、外周血管疾病、瓣膜性心脏病和静脉血栓栓塞复合事件)进行了次要分析。

在170万医疗保险受益人中,2939人被诊断为SDH。SDH后4周,患者发生动脉缺血性事件的风险显著增加(风险比为3.6 [95%CI为1.9-5.5])。SDH诊断与超过4周的动脉缺血性事件无显著相关性。在次要分析中,SDH后4周内,患者发生缺血性卒中的风险增加(风险比为4.2 [95%CI为2.1-7.3]),但心肌梗死的风险不增加(风险比为0.8[95%CI为0.2-1.7])。抗血栓治疗适应症强的患者发生动脉缺血性事件的风险与初步分析的患者相似,但无此适应症的患者发生动脉缺血性事件的风险并不增加。

由此可见,在医疗保险受益人中,研究人员发现在非创伤性SDH后的4周内,由于缺血性卒中风险的增加,动脉缺血性事件的风险增加。这种风险的增加可能是由于SDH诊断后抗血栓治疗的中断所致。

原始出处:

Santosh B. Murthy.et al.Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic Events.stroke.2020.https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.028510

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893280, encodeId=66951893280c7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 14 13:01:18 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054170, encodeId=934220541e055, content=<a href='/topic/show?id=39e8e362693' target=_blank style='color:#2F92EE;'>#硬膜下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73626, encryptionId=39e8e362693, topicName=硬膜下)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sat Jan 02 03:01:18 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025507, encodeId=8726202550ea6, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Apr 05 04:01:18 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335297, encodeId=21eb133529ea0, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Thu Mar 19 10:01:18 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893280, encodeId=66951893280c7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 14 13:01:18 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054170, encodeId=934220541e055, content=<a href='/topic/show?id=39e8e362693' target=_blank style='color:#2F92EE;'>#硬膜下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73626, encryptionId=39e8e362693, topicName=硬膜下)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sat Jan 02 03:01:18 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025507, encodeId=8726202550ea6, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Apr 05 04:01:18 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335297, encodeId=21eb133529ea0, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Thu Mar 19 10:01:18 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893280, encodeId=66951893280c7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 14 13:01:18 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054170, encodeId=934220541e055, content=<a href='/topic/show?id=39e8e362693' target=_blank style='color:#2F92EE;'>#硬膜下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73626, encryptionId=39e8e362693, topicName=硬膜下)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sat Jan 02 03:01:18 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025507, encodeId=8726202550ea6, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Apr 05 04:01:18 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335297, encodeId=21eb133529ea0, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Thu Mar 19 10:01:18 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
    2020-04-05 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893280, encodeId=66951893280c7, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Feb 14 13:01:18 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054170, encodeId=934220541e055, content=<a href='/topic/show?id=39e8e362693' target=_blank style='color:#2F92EE;'>#硬膜下#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73626, encryptionId=39e8e362693, topicName=硬膜下)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sat Jan 02 03:01:18 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025507, encodeId=8726202550ea6, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Sun Apr 05 04:01:18 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335297, encodeId=21eb133529ea0, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Thu Mar 19 10:01:18 CST 2020, time=2020-03-19, status=1, ipAttribution=)]